BRM424 / BRIM Biotech - LARVOL DELTA

Current and Emerging Therapeutic Strategies for the Management of Neurotrophic Keratitis. (PubMed, Drugs) - "Emerging therapeutic drug options include insulin drops, BRM424, CSB-001 and varenicline. The aim of this Current Opinion is to introduce and review this field for the general reader, paying particular attention to emerging drug therapies for neurotrophic keratitis."

Journal • Infectious Disease • Keratitis • Ocular Inflammation • Ophthalmology • Transplantation

Assessment of the Initial Efficacy and Safety of BRM424 Ophthalmic Solutions in Patients With Neurotrophic Keratitis (clinicaltrials.gov) - P2 | N=12 | Recruiting | Sponsor: BRIM Biotechnology Inc. | Not yet recruiting ➔ Recruiting

Enrollment open • Keratitis • Ocular Inflammation • Ophthalmology

Assessment of the Initial Efficacy and Safety of BRM424 Ophthalmic Solutions in Patients With Neurotrophic Keratitis (clinicaltrials.gov) - P2 | N=12 | Not yet recruiting | Sponsor: BRIM Biotechnology Inc. | N=48 ➔ 12 | Trial completion date: May 2025 ➔ Nov 2025 | Trial primary completion date: Jan 2025 ➔ Aug 2025

Enrollment change • Trial completion date • Trial primary completion date • Keratitis • Ocular Inflammation • Ophthalmology

Assessment of the Safety and Efficacy of BRM424 Ophthalmic Solutions in Patients With Neurotrophic Keratitis (clinicaltrials.gov) - P2 | N=48 | Not yet recruiting | Sponsor: BRIM Biotechnology Inc.

New P2 trial • Keratitis • Ocular Inflammation • Ophthalmology